Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: Retrospective review at MD Anderson

Journal for ImmunoTherapy of Cancer

Volumn 6, Issue 1, 2018, Pages

  Wang, Yinghong ^a   Abu Sbeih, Hamzah ^a   Mao, Emily ^b   Ali, Noman ^b   Ali, Faisal Shaukat ^a   Qiao, Wei ^a   Lum, Phillip ^a   Raju, Gottumukkala ^a   Shuttlesworth, Gladis ^a   Stroehlein, John ^a   Diab, Adi ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Colitis; Diarrhea; Immune checkpoint inhibitor; Overall survival

Indexed keywords

ATEZOLIZUMAB; CORTICOSTEROID; INFLIXIMAB; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; ARTICLE; BACTEREMIA; CANCER STAGING; CANCER SURVIVAL; CANDIDIASIS; COLITIS; DIARRHEA; ENDOSCOPY; FEMALE; GASTROENTERITIS; HEMATOLOGIC MALIGNANCY; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MELANOMA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOLID MALIGNANT NEOPLASM; STAPHYLOCOCCAL SKIN INFECTION; TREATMENT OUTCOME; URINARY TRACT INFECTION; COMPLICATION; MIDDLE AGED; NEOPLASM; PATHOLOGY; TEXAS; UNITED STATES;

ANTIBODIES, MONOCLONAL; COLITIS; DIARRHEA; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; TEXAS; UNITED STATES;

EID: 85046665351     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-018-0346-6     Document Type: Article

References (30)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74.
2. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803-13.
3. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung Cancer. N Engl J Med. 2015;373:1627-39.
4. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-54.
5. Ribas A, Hamid O, Daud A, et al. Association of Pembrolizumab with Tumor Response and Survival among Patients with Advanced Melanoma. JAMA. 2016;315:1600-9.
6. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med. 2017;377:1345-56.
7. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563-7.
8. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372:311-9.
9. Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515:558-62.
10. Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Euro j cancer (Oxford, England: 1990). 2016;54:139-48.
11. Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals oncol off j Euro Soc Med Oncol. 2017;28:iv119-iv42.
12. Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current diagnosis and Management of Immune Related Adverse Events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol. 2017;8:49.
13. Valsecchi ME. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:1270.
14. Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J immun cancer. 2017;5:95.
15. Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in resected and Unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin cancer res an off j Am Assoc Cancer Res. 2016;22:886-94.
16. Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of Nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J clin oncol off j Am Soc Clin Oncol. 2017;35:785-92.
17. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5:649-55.
18. Wang Y, Abu-Sbeih H, Mao E, et al. Endoscopic and histologic features of immune checkpoint inhibitor-related colitis. IBD Journal. 2018; (in press)
19. Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin cancer res an off j Am Assoc Cancer Res. 2007;13:6681-8.
20. Sarnaik AA, Yu B, Yu D, et al. Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin can res an off j Am Assoc Cancer Res. 2011;17:896-906.
21. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J clin oncol off j Am Soc Clin Oncol. 2006;24:2283-9.
22. Horvat TZ, Adel NG, Dang TO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with Ipilimumab at memorial Sloan Kettering Cancer center. J clin oncol off j Am Soc Clinical Oncol. 2015;33:3193-8.
23. Chaput N, Lepage P, Coutzac C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Annals oncol off j Euro Soc Med Oncol. 2017;28:1368-79.
24. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J clin oncol off j Am Soc Clin Oncol. 2012;30:2691-7.
25. Shoushtari AN, Friedman CF, Navid-Azarbaijani P, et al. Measuring toxic effects and time to treatment failure for Nivolumab plus Ipilimumab in melanoma. JAMA oncol. 2018;4:98-101.
26. Cormier JN, Xing Y, Ding M, et al. Ethnic differences among patients with cutaneous melanoma. Arch Intern Med. 2006;166:1907-14.
27. Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Annals oncol off j Euro Soc Med Oncol. 2017;28:2377-85.
28. Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:1270-1.
29. Dadu R, Zobniw C, Diab A. Managing adverse events with immune checkpoint agents. Cancer j (Sudbury, Mass). 2016;22:121-9.
30. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51-60.